Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

Rhea-AI Summary

Emergent BioSolutions (NYSE:EBS) announced Saudi Food and Drug Authority approval of ACAM2000 [Smallpox and Mpox (Vaccinia) Vaccine, Live] for preventing smallpox and mpox in individuals at high risk of infection.

ACAM2000 is the first Emergent product licensed by SFDA and includes boxed warnings for serious potential complications.

Positive

• SFDA approves ACAM2000 for high-risk smallpox and mpox prevention in Saudi Arabia
• ACAM2000 becomes the first Emergent product licensed by the Saudi regulator
• Expanded international regulatory footprint following prior mpox indication approval in Singapore

Negative

• Serious complications reported, including myocarditis and pericarditis at 5.7 per 1000 primary vaccinees
• Risk of severe outcomes such as encephalitis, progressive vaccinia, eczema vaccinatum, and fetal death
• ACAM2000 contraindicated in individuals with severe immunodeficiency, limiting eligible population

News Market Reaction – EBS

+2.39%

6 alerts

+2.39% Session close to close

+2.9% Peak in 32 min

$439.08M Market Cap

0.1x Rel. Volume

In the May 18 session, EBS gained 2.39%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.9% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Saudi regulatory approval for ACAM2000 in high‑risk individuals, extend...

Analysis

This announcement highlights Saudi regulatory approval for ACAM2000 in high‑risk individuals, extending the product’s recent geographic and indication momentum after the Singapore decision. It reinforces Emergent’s focus on biodefense and global preparedness against smallpox and mpox, which have seen more than 137,000 cases and over 300 deaths globally since 2022. Investors may watch for follow‑on procurement contracts, real-world uptake, and how safety considerations are managed in broader deployment.

Key Figures

Global mpox cases: more than 137,000 cases Global mpox deaths: more than 300 deaths Myocarditis/pericarditis rate: 5.7 per 1000 primary vaccinees +2 more

5 metrics

Global mpox cases more than 137,000 cases Since start of 2022 global mpox outbreak

Global mpox deaths more than 300 deaths Since start of 2022 global mpox outbreak

Myocarditis/pericarditis rate 5.7 per 1000 primary vaccinees Suspect myocarditis and pericarditis cases following ACAM2000 vaccination

Myocarditis/pericarditis CI 95% CI: 1.9–13.3 per 1000 Confidence interval around myocarditis/pericarditis rate in primary vaccinees

Mpox outbreak start 2022 Year global mpox outbreak referenced in article began

Historical Context

5 past events · Latest: Apr 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 30	Q1 2026 earnings	Positive	+2.9%	Revenue, profitability, refinancing and major government contracts lifted shares modestly.
Apr 30	Regulatory approval	Positive	+3.0%	Singapore expanded ACAM2000 indication to mpox prevention for high‑risk adults.
Apr 29	Manufacturing contract	Positive	-2.9%	Multi‑year SAB-142 manufacturing deal worth about $50M coincided with share decline.
Apr 29	Awareness partnership	Neutral	-2.9%	NARCAN awareness initiative in Canada released alongside a negative price reaction.
Apr 28	Strategic partnership	Positive	+2.5%	Substipharm JE vaccine manufacturing and distribution deal supported a modest price gain.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive operational and regulatory news has more often aligned with modest price gains, but some partnerships saw negative reactions, indicating mixed follow-through.

Recent Company History

Over the past month, Emergent reported Q1 2026 revenue of $156.1 million with positive net income and adjusted EBITDA, refinanced a $150 million term loan, and secured sizeable government and manufacturing contracts, including ≈$34.5 million with Substipharm and ≈$50 million with SAB Biotherapeutics. It also expanded ACAM2000’s indication in Singapore and pursued awareness initiatives for NARCAN. The new Saudi approval for ACAM2000 extends this pattern of biodefense and international market developments.

Key Terms

myocarditis, pericarditis, encephalitis, encephalomyelitis, +4 more

8 terms

myocarditis medical

"Serious complications that may follow either primary or revaccination with ACAM2000® include myocarditis and/or pericarditis"

Inflammation of the heart muscle that can weaken the heart’s ability to pump and cause symptoms such as chest pain, shortness of breath, or abnormal heart rhythms. Investors care because myocarditis can affect healthcare costs, clinical trial outcomes, regulatory decisions, product safety perceptions, workforce availability, or lead to legal and reputational risks for companies, similar to how a car engine problem can halt a business until it's fixed.

pericarditis medical

"Serious complications that may follow either primary or revaccination with ACAM2000® include myocarditis and/or pericarditis"

Pericarditis is inflammation of the thin sac that surrounds the heart, like irritation of a protective sleeve or a balloon around the organ. It can cause chest pain, fatigue and other symptoms and is important to investors because cases linked to a drug, vaccine or medical device can change regulatory decisions, affect sales and trigger safety reviews or legal risk, which can move a company’s stock and future outlook.

encephalitis medical

"Serious complications that may follow either primary or revaccination with ACAM2000® include myocarditis and/or pericarditis, ischemic heart disease and non-ischemic dilated cardiomyopathy, encephalitis, encephalomyelitis"

Encephalitis is swelling or inflammation of the brain, usually caused by a viral infection or an immune system reaction, and can produce fever, confusion, seizures or lasting neurologic problems. Investors should care because encephalitis can drive clinical trial risks, product safety concerns, regulatory scrutiny, higher healthcare costs and sudden changes in demand for treatments—akin to an engine failure that can stall a company’s development or revenue plans.

encephalomyelitis medical

"ischemic heart disease and non-ischemic dilated cardiomyopathy, encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia"

Encephalomyelitis is inflammation of the brain and spinal cord that can be caused by infections, autoimmune reactions, or other triggers; think of it as swelling that disrupts the body’s central processing and wiring. It matters to investors because the condition can drive demand for diagnostics, treatments, and clinical trials, affect regulatory reviews and healthcare costs, and influence the valuation of companies developing relevant therapies or tests.

encephalopathy medical

"encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia (vaccinia necrosum), generalized vaccinia"

Encephalopathy is a general term for any condition that causes the brain to work poorly due to illness, toxins, lack of oxygen, or metabolic problems, producing confusion, sleepiness, memory trouble, or seizures. Investors track it because its occurrence can affect clinical trial results, patient safety, regulatory decisions, treatment costs, and liability risk—like a dashboard warning light that signals bigger problems for a drug, device, or healthcare business.

progressive vaccinia medical

"encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia (vaccinia necrosum), generalized vaccinia"

A rare, serious infection caused when the vaccinia virus (used in some smallpox vaccines) keeps growing in someone whose immune system can't control it, producing expanding, long‑lasting sores and sometimes spreading to internal organs. Investors should care because treatments, vaccines, or diagnostic tools tied to preventing or managing this condition can affect regulatory risk, liability exposure, clinical trial design, and market potential for companies working on orthopoxvirus therapies; think of it as a small uncontrolled fire that reveals gaps in defenses and creates demand for fixes.

generalized vaccinia medical

"progressive vaccinia (vaccinia necrosum), generalized vaccinia, severe vaccinial skin infections"

A rare adverse reaction to live vaccinia virus vaccines in which the vaccine virus spreads from the injection site and causes multiple skin lesions, sometimes with fever and other symptoms; it is usually self-limited but can be serious in people with weakened immune systems. Investors care because such safety events can slow or halt clinical programs, trigger regulatory review, and change public confidence in vaccines — like a localized problem that, if it spreads, can signal larger operational or regulatory risks.

stevens-johnson syndrome medical

"erythema multiforme major (including STEVENS-JOHNSON SYNDROME), eczema vaccinatum resulting in permanent sequelae or death"

A rare but serious medical condition where the skin and mucous membranes blister and peel away, similar to a severe burn that affects large areas of the body and often requires hospital care. For investors it matters because it is a known, sometimes drug-triggered safety issue that can halt clinical trials, prompt regulatory warnings or recalls, and lead to large legal and financial consequences for companies producing implicated medicines or devices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox  (Vaccinia) Vaccine, Live], for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection. This follows Emergent’s recent announcement that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000^® [Smallpox and Mpox (Vaccinia) Vaccine, Live] to include prevention of mpox disease in adults determined to be at high risk for mpox infection.

“We are pleased to receive this approval for ACAM2000^® from SFDA for immunization against smallpox and mpox in high-risk individuals,” said Simon Lowry, chief medical officer of Emergent. “ACAM2000^® is the first Emergent product to be licensed by the SFDA and demonstrates the company’s intent to collaborate with governments in the Gulf region and around the world as awareness and adoption of biodefense preparedness strategies continues to increase around the world.”

Smallpox is considered a credible bioterror threat by experts, and its mortality makes it a potential high-impact threat with health, economic and national security implications.¹ Mpox virus is part of the same family of viruses as variola virus, the virus that causes smallpox. Since the start of the global outbreak of mpox in 2022, there have been more than 137,000 confirmed cases and more than 300 deaths reported globally.²

Emergent specializes in developing, manufacturing and delivering medical countermeasures to governments around the world for national security and health preparedness. These products support how governments respond to emergencies and help protect the public from potential threats like smallpox, mpox, anthrax and botulism.

Indication and Select Important Safety Information for ACAM2000^® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
Indication
ACAM2000^® is indicated for active immunization for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection.

Important Safety Information
Warning: Serious Complications
Myocarditis and pericarditis (suspect cases observed at a rate of 5.7 per 1000 primary vaccinees (95% CI: 1.9-13.3)), encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia, generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including STEVENS-JOHNSON SYNDROME), eczema vaccinatum resulting in permanent sequelae or death, accidental eye infection (ocular vaccinia) which can cause ocular complications that may lead to blindness, and fetal death, have occurred following either primary vaccination or revaccination with ACAM2000^® or other live vaccinia virus vaccines that were used historically.

Contraindications
Do not administer ACAM2000^® to individuals with severe immunodeficiency. These individuals may include persons who are undergoing bone marrow transplantation or persons with primary or acquired immunodeficiency states who require isolation.

Warnings and Precautions
Serious complications that may follow either primary or revaccination with ACAM2000^® include myocarditis and/or pericarditis, ischemic heart disease and non-ischemic dilated cardiomyopathy, encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia (vaccinia necrosum), generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including Stevens-Johnson syndrome), eczema vaccinatum, fetal at 1-877-246-8472 (U.S.), 1-800-768-2304 (Canada), or medicalinformation@ebsi.com; or VAERS at 1-800-822-7967 or https://vaers.hhs.gov. Please see the full Prescribing Information for ACAM2000^® for complete Boxed Warning and safety information.

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. 

Safe Harbor Statement 
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements. 

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

¹Smallpox as a Weapon for Bioterrorism

² Mpox 2022 to 2025 Update: A Comprehensive Review on Its Complications, Transmission, Diagnosis, and Treatment

FAQ

What did Emergent BioSolutions (NYSE:EBS) announce on May 18, 2026 about ACAM2000?

Emergent announced SFDA approval of ACAM2000 for preventing smallpox and mpox in high-risk individuals. According to Emergent, this is its first product licensed by the Saudi regulator, supporting global biodefense preparedness efforts.

Who is eligible to receive ACAM2000 smallpox and mpox vaccine approved by SFDA?

ACAM2000 is indicated for individuals determined to be at high risk for smallpox or mpox infection. According to Emergent, it is for active immunization to prevent these diseases, not for general population use.

What serious side effects are associated with ACAM2000 smallpox and mpox vaccine?

ACAM2000 carries a boxed warning for serious complications, including myocarditis, pericarditis, encephalitis, severe skin reactions, ocular vaccinia, and fetal death. According to Emergent, suspected myocarditis and pericarditis occurred at 5.7 cases per 1000 primary vaccinees.

Why is ACAM2000 contraindicated for people with severe immunodeficiency?

ACAM2000 is not to be given to individuals with severe immunodeficiency because live vaccinia virus can cause serious, potentially life-threatening complications. According to Emergent, this includes people undergoing bone marrow transplantation or with primary or acquired immunodeficiency states needing isolation.

How does the SFDA approval of ACAM2000 affect Emergent BioSolutions' biodefense strategy?

The SFDA approval extends ACAM2000 access to high-risk individuals in Saudi Arabia, aligning with Emergent’s biodefense focus. According to Emergent, this first SFDA license reflects intent to collaborate with Gulf region governments on preparedness strategies.

What other recent regulatory milestone involves ACAM2000 smallpox and mpox vaccine?

Singapore’s Health Sciences Authority recently approved an expanded indication for ACAM2000 to include mpox prevention in high-risk adults. According to Emergent, this follows earlier approvals and supports broader international use in biodefense preparedness.